National Cancer Registration and Analysis Service (NCRAS) (United Kingdom)

Database Contact Data

Sarah Stevens
Associate Director for NDRS
(National Disease Registration Service)
Email: sarah.stevens1@nhs.net

Alternate Contact

N/A

References of Studies Using/Describing Database

1. White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study. Cancers (Basel). 2023 Mar 20;15(6):1863. 

2. Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, Phillips A, Butler J, Burton K, Gornall R, Dobbs S, Glasspool R, Peevor R, Ledermann J, McNeish I, Ratnavelu N, Duncan T, Frost J, Lim K, Michael A, Brockbank E, Gajjar K, Taylor A, Bowen R, Andreou A, Ganesan R, Nicum S, Edmondson R, Clayton R, Balega J, Rolland P, Maxwell H, Fotopoulou C. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. Cancers (Basel). 2023 Jan 4;15(2):337.

3. Paisey SA, Weerasuriya S, Palmer K, White BE, Srirajaskanthan R, Chandrakumaran K, Ramage JK. Primary renal neuroendocrine neoplasms: A systematic literature review, report of four local cases, and original survival analysis of 63 patients from a national registry 2012-2018. J Neuroendocrinol. 2022 Dec;34(12):e13215.

4. M A, S C, J F, C L, A B, L P, Sj S. Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service. Eur J Cancer. 2022 Oct;174:48-56. 

5. White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, Ramage JK. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. Lancet Reg Health Eur. 2022 Sep 23;23:100510. 

6. Aggarwal A, Han L, van der Geest S, Lewis D, Lievens Y, Borras J, Jayne D, Sullivan R, Varkevisser M, van der Meulen J. Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study. Lancet Oncol. 2022 Sep;23(9):1211-1220. 

7. Ng OH, Lunevicius R, Arthur JD. Rising incidence of colorectal cancer in individuals younger than 50 years and increasing mortality from rectosigmoid cancer in England. Colorectal Dis. 2021 Oct;23(10):2637-2646.

8. Wanis HA, Møller H, Ashkan K, Davies EA. The incidence of major subtypes of primary brain tumors in adults in England 1995-2017. Neuro Oncol. 2021 Aug 2;23(8):1371-1382.

9. Lai J, Mak V, Bright CJ, Lyratzopoulos G, Elliss-Brookes L, Gildea C. Reviewing the impact of 11 national Be Clear on Cancer public awareness campaigns, England, 2012 to 2016: A synthesis of published evaluation results. Int J Cancer. 2021 Mar 1;148(5):1172-1182. 

10. Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep. 2021 Jan 19;3(2):100232.

Apr 4, 2023 – Now uploaded - National Surveillance System profile from Canada

With data starting in 2003, the National Ambulatory Care Reporting System (NACRS) provides valuable insights into emergency department (ED) visits and lengths of stay reported by participating provinces and territories in Canada. NACRS collects demographic, administrative, clinical and service-specific data for ED, day surgery and other ambulatory care visits.

National Ambulatory Care Reporting System (NACRS) (Canada)

Database Contact Data

Email: help@cihi.ca
Phone: +1 613-241-5543

Alternate Contact

1. CIHI publishes a wealth of publicly available statistics (see https://www.cihi.ca/en/access-data-and-reports).

2. If you’re looking for more detailed information, you can make a custom data request by using their Data Inquiry Form at https://www.cihi.ca/en/data-inquiry-form.

References of Studies Using/Describing Database

1. Burgesson B, Lethbridge L, Haase D, Dunbar M; Published in collaboration with the Health Association of African Canadians. Disparities in Utilization Rates of Total Knee and Hip Arthroplasty Among Racially Visible Populations in Canada: A Retrospective Cohort Analysis. J Arthroplasty. 2025 Apr 11:S0883-5403(25)00336-5.

2. Dick K, Kaczmarek E, Ducharme R, Bowie AC, Dingwall-Harvey ALJ, Howley H, Hawken S, Walker MC, Armour CM. Transformer-based deep learning ensemble framework predicts autism spectrum disorder using health administrative and birth registry data. Sci Rep. 2025 Apr 7;15(1):11816.

3. Yin CY, Scott MM, Talarico R, Hakimjavadi R, Kierulf J, Webber C, Hawken S, Moledina A, Manuel D, Hsu A, Tanuseputro P, Fung C, Kaasalainen S, Molnar F, Shamon S, McIsaac DI, Kobewka D. Transfer from long-term care to acute care and risk of new permanent cognitive or physical disability among long-term care residents in Canada: protocol for a retrospective cohort study. BMJ Open. 2025 Jan 20;15(1):e086932.

4. Yao X, Champagne AS, McFaull SR, Thompson W. Temporal trends and characteristics of fall-related deaths, hospitalizations and emergency department visits among older adults in Canada. Health Promot Chronic Dis Prev Can. 2024 Nov;44(11-12):482-487.

5. Mirzadeh P, Kuk JL, Wharton S, Reid RA, Ardern CI. Healthcare outcomes and dispositions in persons with obesity within emergency departments in Ontario, Canada: A cross-sectional analysis of the National Ambulatory Care Reporting System (NACRS), 2018-2022. PLoS One. 2024 Sep 26;19(9):e0311190.

6. Khalid A, Muchaal PK, Julien DA. Human echinococcosis incidence in Canada: A retrospective descriptive study using administrative hospital and ambulatory visit data, 2000-2020. Can Commun Dis Rep. 2024 Sep 5;50(9):305-311.

7. Dengler J, Perlman M, Jennett M, Marcon E, Guilcher S. An Examination of Utilization Rates Over Time of Nerve and Tendon Transfers in Canada to Improve Upper Limb Function in Cervical Spinal Cord Injury. Plast Surg (Oakv). 2024 Aug;32(3):367-373.

8. Brissette V, Kapral MK, Yu B, Fang J, Odugbemi T, Shamy M, Fahed R, Dowlatshahi D, Gocan S, Martineau I. Seasonal Variations in Stroke Occurrence. Neuroepidemiology. 2024 Jul 22:1-10.

9. Ferro MA, Chan CKY, Browne DT, Colman I, Dubin JA, Duncan L. Suicidal Ideation and Attempts Among Youth With Physical-Mental Comorbidity in Canada: Proposal for an Epidemiological Study. JMIR Res Protoc. 2024 Jul 4;13:e57103.

10. Benny C, Hobin E, Andreacchi AT, Schwartz N, Smith BT. Socio-economic inequities in emergency department visits for wholly alcohol-attributable acute and chronic harms in Canada, 2003-2017. Drug Alcohol Rev. 2024 May;43(4):927-936.

Mar 30, 2023: Introducing BADBIR, a UK psoriasis registry

The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a national register of all patients receiving biologic therapy for the treatment of psoriasis in the United Kingdom. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for Psoriasis should be registered in BADBIR. BADBIR has grown to be the largest psoriasis study of its kind globally.

British Association of Dermatologists Biologic Interventions Register (BADBIR) (United Kingdom) **

Database Contact Data

BADBIR
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester M15 6GZ
UNITED KINGDOM
Main Office Phone: +44 0161 306 1896
Email: badbir@manchester.ac.uk

Alternate Contact

N/A

References of Studies Using/Describing Database

1. Williams K, Lada G, Reynolds NJ, Mcelhone K, Evans I, Warren RB, Walton S, Hughes O, Bewley A, Mason K, Kleyn CE. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Clin Exp Dermatol. 2025 Mar 26;50(4):804-811.

2. Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, Sahuquillo-Torralba A, Lunt M, Garcia-Doval I, Sbidian E, Warren RB, Yiu ZZN. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. Br J Dermatol. 2025 Mar 18;192(4):641-652.

3. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Dand N, Barker JN, Smith CH, Griffiths CE. The association of age at psoriasis onset and HLA-C* 06: 02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2024 May;190(5):689-700.

4. Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker JN, Yiu ZZ, Smith CH, Griffiths CE. Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study. British Journal of Dermatology. 2024 Mar;190(3):441-4.

5. Al-Janabi A, Alabas OA, Yiu ZZ, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CE, Warren RB, Laws P. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA dermatology. 2024 Jan 1;160(1):71-9.

6. Al-Janabi A, Martin P, Khan AR, Foulkes AC, Smith CH, Griffiths CE, Morris AP, Eyre S, Warren RB, Ahmed S, Alabas O. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics. Journal of Allergy and Clinical Immunology. 2023 Nov 1;152(5):1237-46.

7. Alabas OA, Mason KJ, Yiu ZZ, Warren RB, Lunt M, Smith CH, Griffiths CE. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2023 Sep;189(3):271-8.

8. Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou A, Davies E, Smith CH, Griffiths CE. Atopic polygenic risk score is associated with paradoxical eczema developing in patients with psoriasis treated with biologics. Journal of Investigative Dermatology. 2023 Aug 1;143(8):1470-8.

9. Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZ. Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies. JAMA dermatology. 2023 Jul 1;159(7):763-71.

10. Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CE, Lunt M, Warren RB, Yiu ZZ. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2023 Jul;189(1):62-70.

Mar 22, 2023: Why are some databases not currently profiled on B.R.I.D.G.E. TO DATA®?

The main goal of B.R.I.D.G.E. is to profile databases from around the world with the most current information. Therefore, B.R.I.D.G.E. profiles databases as new ones are created. We usually work with each database manager to ensure their database profile is complete and accurate. Although we try to include as many profiles on our web site as possible, we unfortunately cannot profile every database.

Subscribe to